Beyond B cells

How Vor Biopharma’s platform could eliminate on-target toxicity for CAR Ts

PureTech Health plc subsidiary Vor Biopharma Inc. plans to combine CAR T therapies with hematopoietic stem cells modified to go unrecognized by CAR Ts. The approach could increase the types of immune cells that can be targeted by this modality for hematologic malignancies and eliminate the on-target toxicities of existing CAR T agents.

PureTech VP Aleks Radovic-Moreno, who is Vor program lead, said tumor-specific targets

Read the full 645 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE